GlassScriptPhysician profile
Erin Merrell
NPI 1992214076
$1,028.59
in general payments reported to CMS, 2019-2025
20 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $55.30 · 2024: $175 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $193.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $155.19 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $90.89 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.08 | 2024-2025 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $61.19 | 2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $60.07 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.84 | 2023-2025 | |
| Pfizer INC. | $31.81 | 2024-2025 | |
| Radius Health, INC. | $29.50 | 2025 | Tymlos |
| Seqirus USA INC | $25.24 | 2024 | Flucelvax |
| Organon LLC | $24.75 | 2025 | Nexplanon |
| Recordati_rare_diseases_inc. | $24.53 | 2025 | Panhematin |
| Aimmune Therapeutics, INC. | $22.02 | 2025 | Zenpep |
| Corcept Therapeutics | $17.56 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16.70 | 2025 | |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.76 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $13.71 | 2023 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $10.38 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.